GlassScriptPhysician profile
Amanda Schwandt
NPI 1366939167
$1,321.09
in general payments reported to CMS, 2019-2025
12 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $490 · 2024: $188 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,321.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $499.57 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator, Vns Therapy |
| Ucb, INC. | $378.43 | 2023-2025 | Briviact, Fintepla, Nayzilam |
| Sk Life Science, INC. | $189.59 | 2023-2025 | Xcopri |
| Pfizer INC. | $54.37 | 2025 | |
| Merz Pharmaceuticals, LLC | $35.78 | 2025 | Xeomin |
| Mallinckrodt Hospital Products INC. | $34.58 | 2025 | Acthar |
| Jazz Pharmaceuticals INC. | $32.19 | 2025 | |
| Revance Therapeutics, INC. | $24.28 | 2024 | Daxxify |
| Acadia Pharmaceuticals INC | $22.60 | 2025 | Daybue |
| Neurelis, INC. | $20.26 | 2024 | Valtoco |
| Alexion Pharmaceuticals, INC. | $15.72 | 2025 | Ultomiris |
| Argenx US, INC. | $13.72 | 2025 | Vyvgart Hytrulo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Schwandt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.